Free Trial

Cryo-Cell International Q3 2023 Earnings Report

Cryo-Cell International logo
$7.83 -0.07 (-0.89%)
(As of 12/20/2024 04:32 PM ET)

Cryo-Cell International EPS Results

Actual EPS
$0.08
Consensus EPS
-$0.05
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

Cryo-Cell International Revenue Results

Actual Revenue
$7.87 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cryo-Cell International Announcement Details

Quarter
Q3 2023
Time
Q3 2023 Earnings Release

Conference Call Resources

Cackling Kamala hates this company (Ad)

Do you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution.

Before that happens, you need to see the details here.

Cryo-Cell International Earnings Headlines

CRYO-CELL International, Inc. trading resumes
Your bank is lying to you.
You might think you have your money in a high-yield savings account, but do you really? The national average APY on savings is just 0.58%, but you can get up to 5.0% APY online with these accounts.
CRYO-CELL International, Inc. trading halted, volatility trading pause
See More Cryo-Cell International Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cryo-Cell International? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cryo-Cell International and other key companies, straight to your email.

About Cryo-Cell International

Cryo-Cell International (NYSEAMERICAN:CCEL) engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

View Cryo-Cell International Profile

More Earnings Resources from MarketBeat

Upcoming Earnings